TABLE 1.
Patient demographics and related clinical and laboratory findings
| Characteristics | Total (n = 991) | Received atorvastatin (n = 421) | Not received atorvastatin (n = 570) | P‐value |
|---|---|---|---|---|
| Age (y) | 61.640 ± 17.003 | 65.46 ± 14.94 | 58.82 ± 17.88 | <.001 |
| Gender | ||||
| Male (%) | 544 (54.89) | 225 (53.44) | 319 (55.97) | .431 |
| Female (%) | 447 (45.11) | 196 (46.56) | 251 (44.03) | |
| Body mass index (kg/m2) | 27.051 ± 4.854 | 27.34 ± 26.49 | 26.81 ± 4.74 | .119 |
| Vital signs | ||||
| Systolic blood pressure (mmHg) | 117.59 ± 20.71 | 118.55 ± 19.65 | 116.95 ± 21.49 | .219 |
| Diastolic blood pressure (mmHg) | 74.69 ± 27.19 | 74.70 ± 11.76 | 74.71 ± 34.58 | .985 |
| Pulse rate (beats/min) | 89.55 ± 15.71 | 89.01 ± 15.83 | 89.94 ± 15.41 | .538 |
| Respiratory rate (breath/min) | 20.64 ± 7.92 | 20.80 ± 10.69 | 20.51 ± 5.06 | .670 |
| O2 saturation (%) | 88.29 ± 7.82 | 88.35 ± 7.04 | 88.25 ± 8.38 | .924 |
| Comorbidities | ||||
| Hypertension (%) | 407 (41.07) | 233 (55.34) | 174 (30.53) | <.001 |
| Diabetes (%) | 303 (30.58) | 117 (27.79) | 186 (32.81) | <.001 |
| Coronary artery disease (%) | 194 (19.58) | 133 (46.08) | 61 (10.70) | <.001 |
| Chronic kidney disease (%) | 102 (10.29) | 37 (8.79) | 65 (11.40) | <.001 |
| Malignancy (%) | 42 (4.24) | 32 (7.60) | 10 (1.75) | .012 |
| COPD/asthma | 87 (8.78) | 38 (9.03) | 49 (8.60) | .813 |
| Baseline laboratory data | ||||
| WBC (cell/μL) | 6.90 (4.63) | 7.20 (4.80) | 6.60 (4.40) | .020 |
| Lymphocyte (cell/μL) | 821.75 (1588.10) | 828.00 (1596.00) | 821.50 (1587.20) | .780 |
| Haemoglobin (g/dL) | 12.41 ± 2.08 | 12.30 ± 2.17 | 12.28 ± 2.14 | .898 |
| INR | 1.20 ± 0.48 | 1.22 ± 0.52 | 1.08 ± 0.20 | .239 |
| PT | 13.09 ± 5.09 | 13.26 ± 5.30 | 12.94 ± 4.96 | .415 |
| PTT | 28.25 ± 12.79 | 27.39 ± 10.87 | 28.93 ± 14.22 | .126 |
| Lactate dehydrogenase | 645.00 (403.00) | 643.00 (404.00) | 659.00 (525.25) | .282 |
| Ferritin | 621.30 (964.00) | 579.10 (812.10) | 750.95 (1134.40) | .508 |
| C‐reactive protein | 54.00 (53.10) | 55.30 (53.30) | 51.50 (51.65) | .040 |
| Erythrocyte sedimentation rate | 52.74 ± 28.41 | 48.20 ± 29.01 | 60.17 ± 26.12 | .021 |
| Creatine phosphokinase | 130.00 (211.00) | 130.00 (206.00) | 136.00 (264.00) | .203 |
| Serum creatinine | 1.40 (1.20) | 1.40 (1.20) | 1.45 (1.08) | <.001 |
| Serum urea | 50.00 (45.00) | 48.20 (41.90) | 52.30 (55.88) | <.001 |
| Procalcitonin | 0.73 (1.85) | 0.49 (1.31) | 1.16 (2.41) | .873 |
| D‐dimer | 799.20 (2434.00) | 709.00 (1257.00) | 1712.50 (3756.75) | .365 |
| Aspartate aminotransferase | 26.00 (27.00) | 25.00 (25.40) | 29.60 (38.13) | .470 |
| Alanine aminotransferase | 37.00 (29.50) | 40.00 (26.40) | 34.40 (39.78) | .490 |
| Medication used to treat COVID‐19 | ||||
| Hydroxychloroquine | 553 (55.80) | 213 (89.67) | 340 (59.65) | .005 |
| Lopinavir/ritonavir | 557 (56.21) | 236 (56.06) | 321 (56.32) | .935 |
| Corticosteroid | 287 (28.96) | 141 (33.49) | 146 (25.61) | .007 |
| Interferon beta‐1a | 372 (37.54) | 170 (40.38) | 202 (35.44) | .112 |
| Remdesivir | 46 (4.64) | 21 (4.99) | 25 (4.39) | .656 |
| Favipiravir | 40 (4.04) | 23 (5.46) | 17 (2.98) | .050 |